May 2021 — May 2022 · Bridgewater, NJ
Shortlisted 750 licensing partners and supported 28 VP-led external discussions by researching pharma portfolios, commercial capabilities, and strategic fit. Built 21 business cases across 22 pharma assets, modeling demand, competition, pricing, and launch scenarios for executive review. Supported a $35M divestiture of 6 drug candidates with commercial forecasts, competitive research, and transaction diligence materials.